Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-9626
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.27 million
Profitability
Miscellaneous
Employees145
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics Inc (NASDAQ:MCRB) issued its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.17. The biotechnology company had revenue of $12.53 million for the quarter, compared to analyst estimates of $10.29 million. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
6 equities research analysts have issued 12 month target prices for Seres Therapeutics' stock. Their forecasts range from $4.00 to $16.00. On average, they expect Seres Therapeutics' stock price to reach $11.60 in the next twelve months. This suggests a possible upside of 290.6% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.
What is the consensus analysts' recommendation for Seres Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.
What are Wall Street analysts saying about Seres Therapeutics stock?
Here are some recent quotes from research analysts about Seres Therapeutics stock:
- 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (7/4/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects." (5/7/2019)
- 3. HC Wainwright analysts commented, "We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success." (5/3/2019)
Has Seres Therapeutics been receiving favorable news coverage?
News headlines about MCRB stock have been trending negative on Saturday, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Seres Therapeutics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Seres Therapeutics.
Are investors shorting Seres Therapeutics?
Seres Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 4,747,400 shares, an increase of 9.7% from the June 15th total of 4,328,500 shares. Based on an average trading volume of 561,100 shares, the days-to-cover ratio is currently 8.5 days. Approximately 22.9% of the shares of the company are sold short. View Seres Therapeutics' Current Options Chain.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Alder Biopharmaceuticals (ALDR), CannTrust (CNTTF), Amneal Pharmaceuticals (AMRX), Eagle Pharmaceuticals (EGRX), Akero Therapeutics (AKRO), Cytokinetics (CYTK), Retrophin (RTRX), MacroGenics (MGNX), Wave Life Sciences (WVE), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Achillion Pharmaceuticals (ACHN), TherapeuticsMD (TXMD), TG Therapeutics (TGTX) and Vectura Group (VEGPF).
What other stocks do shareholders of Seres Therapeutics own?
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)
- Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)
- Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)
- Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
Who are Seres Therapeutics' major shareholders?
Seres Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (17.13%), Nikko Asset Management Americas Inc. (11.79%), Sumitomo Mitsui Trust Holdings Inc. (11.78%), BlackRock Inc. (5.65%), Vanguard Group Inc. (5.01%) and Renaissance Technologies LLC (2.54%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View Institutional Ownership Trends for Seres Therapeutics.
Which major investors are selling Seres Therapeutics stock?
MCRB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jacobs Levy Equity Management Inc., Schroder Investment Management Group, Schroder Investment Management Group, Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp and Lakeview Capital Partners LLC. Company insiders that have sold Seres Therapeutics company stock in the last year include Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Insider Buying and Selling for Seres Therapeutics.
Which major investors are buying Seres Therapeutics stock?
MCRB stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., ARK Investment Management LLC, Vanguard Group Inc., Marshall Wace North America L.P., Marshall Wace LLP, CVI Holdings LLC and Maven Securities LTD. View Insider Buying and Selling for Seres Therapeutics.
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $2.97.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $207.63 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.View Additional Information About Seres Therapeutics.
What is Seres Therapeutics' official website?
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]
MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
